Lanean...
Product review: avelumab, an anti-PD-L1 antibody
Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppress...
Gorde:
| Argitaratua izan da: | Hum Vaccin Immunother |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6605872/ https://ncbi.nlm.nih.gov/pubmed/30481100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1551671 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|